Use of Radiocontrast Agents in CKD and ESRD

Seminars in Dialysis

Volumn 30, Issue 4, 2017, Pages 290-304

  Bahrainwala, Jehan Z ^a   Leonberg Yoo, Amanda K ^a   Rudnick, Michael R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM;

ACUTE KIDNEY FAILURE; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; DIAGNOSTIC IMAGING; HEMODIALYSIS; HUMAN; RADIOGRAPHY;

ACUTE KIDNEY INJURY; CONTRAST MEDIA; HUMANS; KIDNEY FAILURE, CHRONIC; RADIOGRAPHY; RENAL DIALYSIS;

EID: 85017229265     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/sdi.12593     Document Type: Article

References (89)

1. Aubry P, Brillet G, Catella L, Schmidt A, Benard S: Outcomes, risk factors and health burden of contrast-induced acute kidney injury: an observational study of one million hospitalizations with image-guided cardiovascular procedures. BMC Nephrol 17(1):167, 2016
2. James MT, Samuel SM, Manning MA, Tonelli M, Ghali WA, Faris P, Knudtson ML, Pannu N, Hemmelgarn BR: Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: a systematic review and meta-analysis. Circ Cardiovasc Interv 6(1):37–43, 2013
3. Solomon RJ, Mehran R, Natarajan MK, Doucet S, Katholi RE, Staniloae CS, et al.: Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol 4(7):1162–1169, 2009
4. Khwaja A: KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120(4):c179–c184, 2012
5. Er F, Nia AM, Dopp H, Hellmich M, Dahlem KM, Caglayan E, et al.: Ischemic preconditioning for prevention of contrast medium-induced nephropathy: randomized pilot RenPro Trial (Renal Protection Trial). Circulation 126(3):296–303, 2012
6. Susantitaphong P, Eiam-Ong S: Nonpharmacological strategies to prevent contrast-induced acute kidney injury. BioMed Res Int 2014:463608, 2014
7. Weisbord SD, Gallagher M, Kaufman J, Cass A, Parikh CR, Chertow GM, et al.: Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial. Clin J Am Soc Nephrol 8(9):1618–1631, 2013
8. Weisbord SD, Palevsky PM: Prevention of contrast-induced nephropathy with volume expansion. Clin J Am Soc Nephrol 3(1):273–280, 2008
9. Brar SS, Aharonian V, Mansukhani P, Moore N, Shen AY, Jorgensen M, et al.: Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. Lancet 383(9931):1814–1823, 2014
10. Zhang B, Liang L, Chen W, Liang C, Zhang S: The efficacy of sodium bicarbonate in preventing contrast-induced nephropathy in patients with pre-existing renal insufficiency: a meta-analysis. BMJ Open 5(3):e006989, 2015
11. Zoungas S, Ninomiya T, Huxley R, Cass A, Jardine M, Gallagher M, et al.: Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Ann Intern Med 151(9):631–638, 2009
12. Dorval JF, Dixon SR, Zelman RB, Davidson CJ, Rudko R, Resnic FS: Feasibility study of the RenalGuard balanced hydration system: a novel strategy for the prevention of contrast-induced nephropathy in high risk patients. Int J Cardiol 166(2):482–486, 2013
13. Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, et al.: Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation 124(11):1260–1269, 2011
14. Marenzi G, Ferrari C, Marana I, Assanelli E, De Metrio M, Teruzzi G, et al.: Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial. JACC Cardiovasc Interv 5(1):90–97, 2012
15. Briguori C, Visconti G, Donahue M, De Micco F, Focaccio A, Golia B, et al.: RenalGuard system in high-risk patients for contrast-induced acute kidney injury. Am Heart J 173:67–76, 2016
16. Bell RM, Rear R, Cunningham J, Dawnay A, Yellon DM: Effect of remote ischaemic conditioning on contrast-induced nephropathy in patients undergoing elective coronary angiography (ERICCIN): rationale and study design of a randomised single-centre, double-blind placebo-controlled trial. Clin Res Cardiol 103(3):203–209, 2014
17. Act Investigators: Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation 124(11):1250–1259, 2011
18. Xu R, Tao A, Bai Y, Deng Y, Chen G: Effectiveness of N-acetylcysteine for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 5(9):e003968, 2016
19. Han Y, Zhu G, Han L, Hou F, Huang W, Liu H, et al.: Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol 63(1):62–70, 2014
20. Wang N, Qian P, Yan TD, Phan K: Periprocedural effects of statins on the incidence of contrast-induced acute kidney injury: a systematic review and trial sequential analysis. Int J Cardiol 206:143–152, 2016
21. Quintavalle C, Fiore D, De Micco F, Visconti G, Focaccio A, Golia B, et al.: Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation 126(25):3008–3016, 2012
22. Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, et al.: Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol 105(3):288–292, 2010
23. Mavromatis K: The imperative of reducing contrast dose in percutaneous coronary intervention. JACC Cardiovasc Interv 7(11):1294–1296, 2014
24. Laskey WK, Jenkins C, Selzer F, Marroquin OC, Wilensky RL, Glaser R, et al.: Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol 50(7):584–590, 2007
25. Hawkins IF, Cho KJ, Caridi JG: Carbon dioxide in angiography to reduce the risk of contrast-induced nephropathy. Radiol Clin North Am 47(5):813–825, v-vi, 2009
26. Kian K, Wyatt C, Schon D, Packer J, Vassalotti J, Mishler R: Safety of low-dose radiocontrast for interventional AV fistula salvage in stage 4 chronic kidney disease patients. Kidney Int 69(8):1444–1449, 2006
27. Hill M, Mor MK, Travis L, Ward T, Palevsky PM, Ramkumar M, Weisbord SD: Renal function following fistulography in patients with advanced chronic kidney disease. Ren Fail 35(6):791–795, 2013
28. Fujihara M, Kawasaki D, Shintani Y, Fukunaga M, Nakama T, Koshida R, et al.: Endovascular therapy by CO2 angiography to prevent contrast-induced nephropathy in patients with chronic kidney disease: a prospective multicenter trial of CO2 angiography registry. Catheter Cardiovasc Interv 85(5):870–877, 2015
29. Kelly SC, Li S, Stys TP, Thompson PA, Stys AT: Reduction in contrast nephropathy from coronary angiography and percutaneous coronary intervention with ultra-low contrast delivery using an automated contrast injector system. J Invasive Cardiol 28(11):446–450, 2016
30. Mariani J Jr, Guedes C, Soares P, Zalc S, Campos CM, Lopes AC, et al.: Intravascular ultrasound guidance to minimize the use of iodine contrast in percutaneous coronary intervention: the MOZART (Minimizing cOntrast utiliZation With IVUS Guidance in coRonary angioplasTy) randomized controlled trial. JACC Cardiovasc Interv 7(11):1287–1293, 2014
31. Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, et al.: Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 47(1):254–261, 1995
32. Eng J, Wilson RF, Subramaniam RM, Zhang A, Suarez-Cuervo C, Turban S, et al.: Comparative effect of contrast media type on the incidence of contrast-induced nephropathy: a systematic review and meta-analysis. Ann Intern Med 164(6):417–424, 2016
33. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ: Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 348(6):491–499, 2003
34. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al: American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions: 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58(24):e44–e122, 2011
35. Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, et al.: Pathophysiology of contrast-induced nephropathy. Am J Cardiol 98(6a):14k–20k, 2006
36. Rosenstock JL, Bruno R, Kim JK, Lubarsky L, Schaller R, Panagopoulos G, et al.: The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol 40(3):749–755, 2008
37. Peng F, Su J, Lin J, Niu W: Impact of renin-angiotensin-aldosterone system-blocking agents on the risk of contrast-induced acute kidney injury: a prospective study and meta-analysis. J Cardiovasc Pharmacol 65(3):262–268, 2015
38. Li X, Li T, Fu N, Hu Y, Cong H: Is angiotensin-converting enzyme inhibitor appropriate for contrast-induced nephropathy? A meta-analysis about this field. Int J Cardiol 155(3):486–488, 2012
39. Khan SF, Kalantari K: The use of iodinated contrast media in patients with end-stage renal disease. Semin Dial 27(6):607–610, 2014
40. Lorusso V, Taroni P, Alvino S, Spinazzi A: Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis. Invest Radiol 36(6):309–316, 2001
41. Deray G: Dialysis and iodinated contrast media. Kidney Int Suppl 100:S25–S29, 2006
42. Rodby RA: Preventing complications of radiographic contrast media: is there a role for dialysis? Semin Dial 20(1):19–23, 2007
43. Lehnert T, Keller E, Gondolf K, Schaffner T, Pavenstadt H, Schollmeyer P: Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial Transplant 13(2):358–362, 1998
44. Weisbord SD, Palevsky PM: Iodinated contrast media and the role of renal replacement therapy. Adv Chronic Kidney Dis 18(3):199–206, 2011
45. Cruz DN, Goh CY, Marenzi G, Corradi V, Ronco C, Perazella MA: Renal replacement therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Med 125(1):66–78, e3, 2012
46. Vogt B, Ferrari P, Schonholzer C, Marti HP, Mohaupt M, Wiederkehr M, et al.: Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 111(9):692–698, 2001
47. Cruz DN, Perazella MA, Bellomo R, Bellomo R, Corradi V, de Cal M, et al.: Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Kidney Dis 48(3):361–371, 2006
48. Russo D, Minutolo R, Cianciaruso B, Memoli B, Conte G, De Nicola L: Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 6(5):1451–1458, 1995
49. Heyman SN, Clark BA, Kaiser N, Spokes K, Rosen S, Brezis M, et al.: Radiocontrast agents induce endothelin release in vivo and in vitro. J Am Soc Nephrol 3(1):58–65, 1992
50. Choi MJ, Yoon JW, Han SJ, Choi HH, Song YR, Kim SG, et al.: The prevention of contrast-induced nephropathy by simultaneous hemofiltration during coronary angiographic procedures: a comparison with periprocedural hemofiltration. Int J Cardiol 176(3):941–945, 2014
51. Marenzi G, Bartorelli AL, Lauri G, Assanelli E, Grazi M, Campodonico J, et al.: Continuous veno-venous hemofiltration for the treatment of contrast-induced acute renal failure after percutaneous coronary interventions. Catheter Cardiovasc Interv 58(1):59–64, 2003
52. Marenzi G, Lauri G, Campodonico J, Marana I, Assanelli E, De Metrio M, et al.: Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med 119(2):155–162, 2006
53. Mathew AT, Fishbane S, Obi Y, Kalantar-Zadeh K: Preservation of residual kidney function in hemodialysis patients: reviving an old concept. Kidney Int 90(2):262–271, 2016
54. Shemin D, Bostom AG, Laliberty P, Dworkin LD: Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 38(1):85–90, 2001
55. van der Wal WM, Noordzij M, Dekker FW, Boeschoten EW, Krediet RT, Korevaar JC, et al.: Full loss of residual renal function causes higher mortality in dialysis patients; findings from a marginal structural model. Nephrol Dial Transplant 26(9):2978–2983, 2011
56. Younathan CM, Kaude JV, Cook MD, Shaw GS, Peterson JC: Dialysis is not indicated immediately after administration of nonionic contrast agents in patients with end-stage renal disease treated by maintenance dialysis. AJR Am J Roentgenol 163(4):969–971, 1994
57. Hamani A, Petitclerc T, Jacobs C, Deray G: Is dialysis indicated immediately after administration of iodinated contrast agents in patients on haemodialysis? Nephrol Dial Transplant 13(4):1051–1052, 1998
58. Rudnick MR, Berns JS, Cohen RM, Goldfarb S: Contrast media-associated nephrotoxicity. Semin Nephrol 17(1):15–26, 1997
59. Idee JM, Port M, Dencausse A, Lancelot E, Corot C: Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am 47(5):855–869, vii, 2009
60. Joffe P, Thomsen HS, Meusel M: Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5(7):491–502, 1998
61. Schuhmann-Giampieri G, Krestin G: Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol 26(11):975–979, 1991
62. Saitoh T, Hayasaka K, Tanaka Y, Kuno T, Nagura Y: Dialyzability of gadodiamide in hemodialysis patients. Radiat Med 24(6):445–451, 2006
63. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE: Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356(9234):1000–1001, 2000
64. Grobner T: Gadolinium–a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21(4):1104–1108, 2006
65. Agarwal R, Brunelli SM, Williams K, Mitchell MD, Feldman HI, Umscheid CA: Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrol Dial Transplant 24(3):856–863, 2009
66. Bernstein EJ, Schmidt-Lauber C, Kay J: Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure. Best Pract Res Clin Rheumatol 26(4):489–503, 2012
67. Kay J, Czirjak L: Gadolinium and systemic fibrosis: guilt by association. Ann Rheum Dis 69(11):1895–1897, 2010
68. Boyd AS, Zic JA, Abraham JL: Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56(1):27–30, 2007
69. High WA, Ayers RA, Chandler J, Zito G, Cowper SE: Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56(1):21–26, 2007
70. Moschella SL, Kay J, Mackool BT, Liu V: Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin. N Engl J Med 351(21):2219–2227, 2004
71. Girardi M, Kay J, Elston DM, Leboit PE, Abu-Alfa A, Cowper SE: Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 65(6):1095–1106, 2011
72. Todd DJ, Kagan A, Chibnik LB, Kay J: Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 56(10):3433–3441, 2007
73. Ting WW, Stone MS, Madison KC, Kurtz K: Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 139(7):903–906, 2003
74. Jimenez SA, Artlett CM, Sandorfi N, Derk C, Latinis K, Sawaya H, et al.: Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 50(8):2660–2666, 2004
75. Swaminathan S, High WA, Ranville J, Horn TD, Hiatt K, Thomas M, et al.: Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int 73(12):1413–1418, 2008
76. Gilliet M, Cozzio A, Burg G, Nestle FO: Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 152(3):531–536, 2005
77. Mathur K, Morris S, Deighan C, Green R, Douglas KW: Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: three case reports and review of literature. J Clin Apheresis 23(4):144–150, 2008
78. Lauchli S, Zortea-Caflisch C, Nestle FO, Burg G, Kempf W: Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology 208(3):278–280, 2004
79. Wahba IM, White K, Meyer M, Simpson EL: The case for ultraviolet light therapy in nephrogenic fibrosing dermopathy–report of two cases and review of the literature. Nephrol Dial Transplant 22(2):631–636, 2007
80. Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, et al.: Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 56(1):311–322, 2007
81. Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, et al.: Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology 260(1):105–111, 2011
82. Miskulin D, Rudnick MR: Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure. Waltham, MA: UpToDate, 2016, accessed January 1, 2017
83. Gheuens E, Daelemans R, Mesens S: Dialysability of gadoteric acid in patients with end-stage renal disease undergoing hemodialysis. Invest Radiol 49(8):505–508, 2014
84. Deo A, Fogel M, Cowper SE: Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2(2):264–267, 2007
85. Shabana WM, Cohan RH, Ellis JH, Hussain HK, Francis IR, Su LD, et al.: Nephrogenic systemic fibrosis: a report of 29 cases. AJR Am J Roentgenol 190(3):736–741, 2008
86. Murashima M, Drott HR, Carlow D, Shaw LM, Milone M, Bachman M, et al.: Removal of gadolinium by peritoneal dialysis. Clin Nephrol 69(5):368–372, 2008
87. Hope MD, Hope TA, Zhu C, Faraji F, Haraldsson H, Ordovas KG, et al.: Vascular imaging with ferumoxytol as a contrast agent. AJR Am J Roentgenol 205(3):W366–W373, 2015
88. Vasanawala SS, Nguyen KL, Hope MD, Bridges MD, Hope TA, Reeder SB, Bashir MR: Safety and technique of ferumoxytol administration for MRI. Magn Reson Med 75(5):2107–2111, 2016
89. Wang C, Graham DJ, Kane RC, Xie D, Wernecke M, Levenson M, et al.: Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 314(19):2062–2068, 2015